Search results
7th Pay Commission: Central Govt Employees Likely To Get 3% DA Hike in September - News18
News18· 2 hours ago7th Pay Commission DA Hike: Central government employees are likely to get a bonanza soon as the...
Children Twice As Likely To Develop Type 1 Diabetes If Father Has Condition, Finds Study
Times Now· 4 days agoA new study found that a child is almost twice as likely to develop type 1 diabetes if the father...
Traveling to swing states, NC Gov. Roy Cooper plans to be ‘active’ surrogate for Harris
Durham Herald-Sun· 10 minutes agoAnd Jackson said Harris and her campaign, including surrogates from other states, will continue...
Reduce Colgate Palmolive; target of Rs 2743: Prabhudas Lilladher
CNBC Awaaz· 22 minutes agoPrabhudas Lilladher recommended reduce rating on Colgate Palmolive with a target price of Rs 2743 in its research report dated July 29, 2024.
Congress moves privilege notice against PM Modi, BJP calls it a joke | India News - Times of India
The Times of India· 12 hours agoNEW DELHI: Even as Congress on Wednesday filed a notice of breach of privilege against PM Modi for...
MANU STRIKES TWICE - The Tribune
Tribune India· 2 days agoShortly after 10 in the morning today, the stoicism that’s central to shooting was shed by Manu Bhaker and Sarabjot Singh. After hours of restraint —...
A Twice-Yearly Shot Could Be a “New Breakthrough” For HIV Prevention
them· 6 days agoGetty Images Twice-yearly injections of the drug lenacapavir could offer complete protection from...
Honda needs to rev up as Ola, TVS and Bajaj electric bikes leave it in the dust
Livemint· 4 hours agoInstead, it’s Honda, whose cheap and cheerful Super Cub motorbike deserves to be recognized as the...
The 10 Best K-pop Albums Of 2024 So Far: From Seventeen-17 Is Right Here To Twice- With You-Th
Koimoi· 1 day agoIf you are a huge fan of K-pop and a multistan, then you are at the right place because here are the...
AIDS 24: Prioritise at risk populations for trials, testing and treatment
Clinical Trials Arena· 37 minutes agoPURPOSE 2 is A Phase III study assessing twice-yearly lenacapavir for PrEP among men, transgender...